Lumiera Health – Date of the Annual General and Special Meeting of Shareholders and Addition to the Board of Directors

Montreal, Quebec–(Newsfile Corp. – October 4, 2023) – Lumiera Health Inc. (TSXV: NHP) (the “Company” or “Lumiera“), a company specializing in the development and commercialization of natural health products, is pleased to announce that it will hold its Annual General and Special Shareholder Meeting on November 14, 2023. The record date for the meeting is October 10, 2023.

Furthermore, the Company is pleased to announce that Mr. Shawn Moniz has agreed to join the Board of Directors, effective immediately. Mr. Moniz will bring to the Company tremendous expertise.

Mr. Moniz has over 22 years of experience as a strategic marketing and brand strategist in the field of customer relationship management (“CRM”) and consumer product goods (“CPG”), where he was involved in brand positioning and loyalty focus, marketing automation, digital data strategy and omni-channel data driven marketing. Mr. Moniz has served as Vice President, CRM Strategic Solutions in his most recent occupation before founding Happy Belly, where he currently serves as CEO. Mr. Moniz has delivered strategic growth solutions to numerous Fortune 500 companies in the health care vertical such as Pfizer, Astellas, Bayer, GSK and many others. Mr. Moniz’s background and experience in the healthcare field will play a vital role in Lumiera’s future.

The Company looks forward to updating shareholders on its corporate plans.

The Board of Directors thanks Shareholders, Customers, and Suppliers for their patience over the past months. Further details will be provided when available.

About Lumiera Health

Lumiera specializes in the development and commercialization of consumer products for the natural health industry. The Company sells herbal tonics and natural supplements through its Holizen Laboratories division, with a diverse portfolio including a line of innovative sleep aids. The Company is also commercializing a unique topical product line acting on the endocannabinoid system, without the use of cannabis, that provides an innovative solution for chronic pain and inflammation. A pioneer in the natural health innovation space, the Lumiera brand is rooted in the core values of science, nature and compassion. Our goal is to make people’s lives better by developing natural health and wellness products that are effective, safe and trustworthy.

For more information visit: www.lumiera.ca.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information: Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions indicate such “forward-looking information” as they relate to Lumiera. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Lumiera’s current views and intentions with respect to future events, and current information available to Lumiera, and are subject to certain risks, uncertainties and assumptions.

Such risks and uncertainties include, among others, the risk factors included in Lumiera’s annual management’s discussion and analysis for the year ended November 30, 2022, which is available under the issuer’s SEDAR profile at sedarplus.ca. Material factors or assumptions were applied in providing forward-looking information. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Lumiera in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Lumiera does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Lumiera undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

For further information: Mr. André Rancourt, 514.500.0059, info@lumiera.ca

CO: Lumiera Health Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/182825